BPDCN

Diagnosis, management challenging for pediatric BPDCN
December 08, 2020

A 13-year-old boy presenting an asymptotic dark violaceous infiltrated nodular lesion located on the left cheek was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy that often presents with skin manifestations.

Target therapies under study to treat BPDCN
December 08, 2020

Researchers are looking at treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematolymphoid malignancy, with investigational agents equipped with different mechanisms of action, including XmAb14045 and IMGN632.

Data describes BPDCN’s clinical, biological features and patient outcomes
November 12, 2020

A recently published article details the clinical and biological features, and patient outcomes of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematopoietic malignancy.

Venetoclax monotherapy for cutaneous BPDCN
November 11, 2020

B-cell lymphoma-2 inhibitor venetoclax has shown in clinical studies to improve symptoms with minimal toxicity in patients with cutaneous blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer that can be rapidly fatal without treatment.

CD123-targeted therapies promising in BPDCN and AML
October 06, 2020

Several CD123-targeted therapies have been in development following the FDA’s 2018 approval of tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), but important questions remain when it comes to targeting CD123 in myeloid malignancies.

Tagraxofusp treatment for BPDCN continues to evolve
October 05, 2020

A recent paper details the different ways scientists are investigating tagraxofusp to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic malignancy that often presents with skin manifestations.

Tagraxofusp comparable to other chemo regimens as first-line therapy
September 04, 2020

Findings from a recent study support current recommendations to treat patients with BPDCN with tagraxofusp or hyper-CVAD as first-line treatments, then with allogeneic stem cell transplant if patients are eligible.

What dermatologists should know about blastic plasmacytoid dendritic cell neoplasm
September 03, 2020

One expert who is part of a small worldwide group of dedicated scientists and clinicians working to build BPDCN awareness among specialists offers insights from his research for dermatologists.

FDA-approved treatment puts rare cancer with skin manifestations on the map
July 31, 2020

Those who study blastic plasmacytoid dendritic cell neoplasm (BPDCN) struggle to make dermatologists and others aware that the rare hematologic malignancy that often first presents with skin manifestations exists.